PERL is a the largest monocentric research project on 18F-FDG Positron Emission Radiomics in Lymphoma, promoted thanks to a dedicated national grant Ricerca Finalizzata
(code GR-2019-12370372), won in 2020 by a dedicated research team at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome (Italy).
to investigate if baseline 18F-FDG-PET/CT radiomics could predict progression free survival (PFS) in a large retrospective cohort of patients with high-grade lymphoma.
to evaluate the prognostic role of PET/CT parameters in term of overall survival (OS).
to correlate PET/CT parameters with other clinical variables at baseline.
Today, patients with poor prognosis undergo to the standard first-line treatment, so the risk of under-treatment still remain.
Baseline 18F-FDG PET/CT could drive personalized treatment in patients with high-grade lymphoma, allowing intensified treatment schemes in aggressive disease.
To be informed and involved as patients or patients’ association in PERL and further projects, please follow the instructions on the Contact page.
If informative, the PERL project may have an important impact on the health system and could result in the use of radiomics in the clinical work-up of patients with lymphoma.
Moreover, study may lead to potential funding delivered by public and private organizations at national and international level interested in research about new imaging-derived biomarkers in the personalized medicine in lymphoma.
To be informed and involved as research institutions and companies in further projects, please follow the instructions on the Contact page.
Dr. Salvatore Annunziata, MD, PhD, Nuclear Physician
PERL PI, Head of TracerGLab GSTeP
Dr. Angela Collarino, MD, PhD, Nuclear Physician
PERL co-PI, TracerGLab GSTeP, Direzione Scientifica IRCCS
Dr. Elizabeth Triumbari, MD, Nuclear Physician
PERL fellow, TracerGLab GSTeP